Page 2 - Induced Xerostomia News Today : Breaking News, Live Updates & Top Stories | Vimarsana
MeiraGTx Holdings plc (MGTX) Announces $25M Investment from Johnson & Johnson Innovation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
MeiraGTx Reports Second Quarter 2022 Financial and Operational Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
MeiraGTx Reports First Quarter 2021 Financial and Operational Results
LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress.
“During the first quarter of 2021, we continued to advance our clinical and preclinical programs, as well as our proprietary cGMP manufacturing process. We are progressing rapidly with our riboswitch gene regulation technology platform and we are excited to share
in-vivo data later this year,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “This will be an important year for MeiraGTx as the Company prepares for the initiation of two Phase 3 pivotal trials in X-linked retinitis pigmentosa and
MeiraGTx Reports First Quarter 2021 Financial and Operational Results
LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress. During the first quarter of 2021, we continued to advance our clinical and preclinical programs, as well as our proprietary cGMP manufacturing process. We are progressing rapidly with our riboswitch gene regulation technology platform and we are excited to share
in-vivo data later this year, said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. This will be an important year for MeiraGTx as the Company prepares for the initiation of two Phase 3 pivotal trials in X-linked retinitis pigmentosa and
MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR
- Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Xerostomia
- Completed Build of Internal cGMP Plasmid and DNA Manufacturing Facility
- Strengthened Balance Sheet and Extended Cash Runway into Mid-2023
- First in-vivo Data from Riboswitch Gene Regulation Platform to be Presented in 2021
LONDON and NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent progress.
vimarsana © 2020. All Rights Reserved.